Bionomics is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system (CNS) disorders. Based in Adelaide, Australia with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation

    23 May 2018

    Download PDF

  • Bionomics Presents BNC101 and BNC105 Data at the American Association for Cancer Research Conference

    13 April 2018

    Download PDF

  • Phase 2 Clinical Trial of BNC210 for Treatment of Post-Traumatic Stress Disorder Fully Recruited

    11 April 2018

    Download PDF


Latest Analyst Report